Related Experiment Video
Updated: Feb 19, 2026
06:07
Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
Published on: February 5, 2020
6.2K
PD-1 expression and clinical PD-1 blockade in B-cell lymphomas
Zijun Y Xu-Monette1, Jianfeng Zhou2, Ken H Young1,3
1Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Blood
|November 10, 2017
Summary
PD-1 blockade immunotherapy shows significant promise in advanced cancers, particularly B-cell lymphomas. High response rates are observed in classical Hodgkin lymphoma and some non-Hodgkin lymphomas.
Area of Science:
- Oncology
- Immunology
- Hematology
Background:
- Programmed cell death protein 1 (PD-1) blockade is effective in advanced cancers.
- PD-1/programmed death-ligand 1 (PD-L1) expression varies across B-cell lymphomas.
- Understanding PD-1/PD-L1 in B-cell lymphomas is crucial for immunotherapy.
Purpose of the Study:
- To review PD-1/PD-L1 expression in B-cell lymphomas.
- To summarize current PD-1 blockade immunotherapy trials in these lymphomas.
- To discuss mechanisms, biomarkers, and challenges of PD-1 blockade.
Main Methods:
- Review of literature on PD-1/PD-L1 expression.
- Analysis of clinical trial data for PD-1 blockade in B-cell lymphomas.
- Discussion of biological mechanisms and clinical implications.
Main Results:
- High objective response rates (ORRs) for anti-PD-1 in classical Hodgkin lymphoma (65-87%).
- Promising results for nivolumab in relapsed/refractory B-cell non-Hodgkin lymphomas.
- Variable ORRs for pembrolizumab in primary mediastinal large B-cell lymphoma (35%) and CLL (0-44%).
- PD-1 expression identified in T cells of CLL and follicular lymphoma, but not mantle cell lymphoma.
Conclusions:
- PD-1 blockade is highly effective in classical Hodgkin lymphoma.
- Immunotherapy shows potential in specific B-cell non-Hodgkin lymphomas.
- PD-1 expression and 9p24.1 alterations are key factors.
- Further research is needed for optimal use and combination therapies.
